NDRA - エンドラ・ライフ・サイエンシズ (ENDRA Life Sciences Inc.) エンドラ・ライフ・サイエンシズ

 NDRAのチャート


 NDRAの企業情報

symbol NDRA
会社名 ENDRA Life Sciences Inc (エンドラ・ライフ・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company's Nexus 128 system combines light-based thermoacoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing TAEUS for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature in real time; enabling ultrasound to view blood vessels from any angle using only a saline solution contrasting agent unlike Doppler ultrasound which requires precise viewing angles and enabling ultrasound to image blood flow at the capillary level in a region organ or tissue.   エンドラ・ライフ・サイエンシズは米国の医療機器メ―カ―。主に超音波技術の開発に従事する。同社の「Nexus 128」は、光音響画像と超音波を組み合わせた3D断層撮影装置で、臨床前研究において使用される。また、開発中の「TAEUS」は、熱音響を利用した超音波システムで、さまざまな病状の診断や治療に活用できる。本社はミシガン州アナ―バ―。   ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.
本社所在地 3600 Green Court Suite 350 Ann Arbor MI 48105-1570 USA
代表者氏名 Francois Michelon フランソワミッシェロン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 734-335-0468
設立年月日 39264
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数 13人
url www.endrainc.com
nasdaq_url https://www.nasdaq.com/symbol/ndra
adr_tso
EBITDA EBITDA(百万ドル) -7.80746
終値(lastsale) 2.8694
時価総額(marketcap) 11256733.6738
時価総額 時価総額(百万ドル) 11.06294
売上高 売上高(百万ドル) 0.30002
企業価値(EV) 企業価値(EV)(百万ドル) 9.21066
当期純利益 当期純利益(百万ドル) -7.87562
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ENDRA Life Sciences Inc revenues decreased 89% to $6K. Net loss increased from $2.2M to $4.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $271K to $2.5M (expense) Selling/General/Admin. Expense increase of 75% to $2M (expense).

 NDRAのテクニカル分析


 NDRAのニュース

   ENDRA Life Sciences : Provides European Commercialization Update | MarketScreener  2020/03/17 12:40:35 MarketScreener
Executing Tactical Elements of EU Commercial Plan to Support Initial Launch Activities ANN ARBOR, MI / ACCESSWIRE / March 17, 2020 /ENDRA Life Sciences Inc. ,… | March 17, 2020
   ENDRA Life Sciences Renews GE Healthcare Collaboration Agreement  2020/01/15 14:00:00 Yahoo Finance
Supports Commercialization of TAEUS Liver Product Targeting NAFLD-NASH ANN ARBOR, MI / ACCESSWIRE / January 15, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic …
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data  2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
   Can ENDRA Life Sciences (NASDAQ:NDRA) Fund Its Growth Plans?  2019/10/28 19:41:26 ACI Information Group
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com…
   ENDRA Life Sciences : Provides European Commercialization Update | MarketScreener  2020/03/17 12:40:35 MarketScreener
Executing Tactical Elements of EU Commercial Plan to Support Initial Launch Activities ANN ARBOR, MI / ACCESSWIRE / March 17, 2020 /ENDRA Life Sciences Inc. ,… | March 17, 2020
   ENDRA Life Sciences Renews GE Healthcare Collaboration Agreement  2020/01/15 14:00:00 Yahoo Finance
Supports Commercialization of TAEUS Liver Product Targeting NAFLD-NASH ANN ARBOR, MI / ACCESSWIRE / January 15, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic …
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data  2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
   Can ENDRA Life Sciences (NASDAQ:NDRA) Fund Its Growth Plans?  2019/10/28 19:41:26 ACI Information Group
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com…
   ENDRA Life Sciences Renews GE Healthcare Collaboration Agreement  2020/01/15 14:00:00 Yahoo Finance
Supports Commercialization of TAEUS Liver Product Targeting NAFLD-NASH ANN ARBOR, MI / ACCESSWIRE / January 15, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic …
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data  2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
   Can ENDRA Life Sciences (NASDAQ:NDRA) Fund Its Growth Plans?  2019/10/28 19:41:26 ACI Information Group
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com…
   ENDRA Life Sciences Reports Completion and Top Level Findings of Second Phase of Robarts Research Institute Liver Fat Feasibility Study  2019/09/26 12:30:00 Yahoo Finance
ANN ARBOR, MI / ACCESSWIRE / September 26, 2019 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a pioneer of enhanced ultrasound technologies, today reported that Robarts Research Institute has completed the second phase of the Thermo Acoustic Enhanced Ultrasound (TAEUS) feasibility study of liver

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エンドラ・ライフ・サイエンシズ NDRA ENDRA Life Sciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)